XtalPi partners with international biopharma on GPCR oral small-molecule drug, deal value tops $400 million

• XtalPi entered a strategic partnership with an unnamed international biopharma to develop an oral small-molecule therapy for a GPCR target.
• Biopharma partner will pay an upfront fee, fund early R&D, provide milestones, royalties; total potential value exceeds USD 400 million.
• Deal follows a completed pilot phase that delivered higher hit rates using XtalPi’s quantum physics, AI-driven screening, XFEP binding predictions.
• Collaboration targets a metabolically relevant GPCR lacking public co-crystal small-molecule structures, a hurdle for traditional screening.
• XtalPi will run closed-loop DMTA cycles using generative AI, simulations, multi-agent orchestration, automated synthesis to optimize potency, selectivity, ADMET.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtalpi Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606100845PR_NEWS_USPR_____CN80207) on June 10, 2026, and is solely responsible for the information contained therein.